SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $122
SVB Leerink analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $120 to $122.
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Merck & Co Inc’s (NYSE:MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the…
Merck & Co Q4 Adj. EPS $1.62 Beats $1.54 Estimate, Sales $13.80B Beat $13.67B Estimate
Merck & Co (NYSE:MRK) reported quarterly earnings of $1.62 per share which beat the analyst consensus estimate of $1.54 by 5.19 percent. This is a 10 percent decrease over earnings of $1.80 per share from the same period
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Where Merck & Co Stands With Analysts
Merck & Co (NYSE:MRK) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent…
SVB Leerink Maintains Outperform on Merck & Co, Raises Price Target to $120
SVB Leerink analyst Daina Graybosch maintains Merck & Co (NYSE:MRK) with a Outperform and raises the price target from $112 to $120.
Seagen’s Tukysa Becomes First FDA-Approved Treatment For HER2-Positive Metastatic Colorectal Cancer
The FDA has granted accelerated approval to Seagen Inc’s (NASDAQ:SGEN) Tukysa (tucatinib) in combination with trastuzumab for colorectal cancer. The approval covers…
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Reported Late Tuesday, Merck Selects Perceiv AI For Inaugural Digital Sciences Studio Cohort
Joining the cohort in Cambridge, MA, Perceiv AI will receive direct funding and mentorship from Merck, Northpond Ventures, and McKesson Ventures to advance its prognostic platform focused on multimodal data in neurodegenerative diseases.